SIRT With Tremelimumab and Durvalumab for Resectable HCC
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The goal of this research study is to evaluate the safety and tolerability of tremelimumab
and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in
participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery.
The names of the interventions involved in this study are:
- Durvalumab (a type of immunotherapy)
- Tremelimumab (a type of immunotherapy)
- Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere
bead)